Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...
The health expert has spoken out about the healing properties of kiwifruit - which is packed with antioxidants and can help ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
According to studies, eating the fruit once every day is enough to protect your DNA by 60% - reducing your risk of chronic ...
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...
OS Therapies, Inc., a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced that it received a Notice of Allowance from the United ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.